文献速递骨软组织肉瘤与黑色素瘤

老年黑色素瘤患者的治疗模式及年龄对免疫治疗疗效的影响:ADOREG真实世界多中心注册分析

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.
PubMed 文献 · Eur J Cancer · 2026-02-20

基于德国ADOREG注册的回顾性多中心队列研究,纳入2013至2023年接受肿瘤药物治疗的8213例皮肤黑色素瘤患者,按年龄<75岁与≥75岁分组。老年转移性患者接受的治疗线数更少、手术/放疗/全身治疗比例更低,但一线治疗疗效无差异,免疫治疗选择相似且老年患者以一线抗PD1单药为主,疗效未受损且毒性更低。

要点

  • 老年(≥75岁)转移性黑色素瘤患者接受的治疗线数及手术、放疗、全身治疗比例低于年轻患者。
  • 两年龄组一线治疗疗效无差异(p=0.306),免疫治疗选择相似(p=0.109)。
  • 老年患者以一线抗PD1单药为主,联合免疫检查点抑制剂在年轻患者中更常用,且老年患者毒性更低、PFS与MSS未受损。

核心结论

  • 年龄影响黑色素瘤患者的治疗选择,但老年患者疗效未受损且毒性谱平衡,尤其免疫治疗。

研究设计与样本

  • 回顾性多中心队列研究,基于ADOREG注册,纳入2013至2023年德国皮肤癌中心接受肿瘤药物治疗的皮肤黑色素瘤患者,预设年龄分组<75岁 vs ≥75岁,共病用Charlson共病指数(CCI)汇总。

主要发现

  • 14356例黑色素瘤患者中8213例符合纳入标准,<75岁6063例、≥75岁2150例。
  • 3646例转移性疾病患者中,老年患者接受的治疗线数更少,接受手术、放疗和全身治疗的可能性更低。
  • 两年龄组任何一线治疗的疗效无差异(p=0.306)。
  • 任何线免疫治疗选择两组相似(p=0.109),但老年患者主要接受一线抗PD1单药治疗,而年轻患者更偏好联合免疫检查点抑制剂。
  • 疗效未受损(PFS和MSS:p>0.05),同时毒性发生率更低,该模式在各CCI类别中持续存在。

临床怎么用

  • 老年黑色素瘤患者可考虑一线抗PD1单药免疫治疗,疗效未受损且毒性更低。
  • 年龄不应单独作为排除有效治疗的理由,但需结合共病评估个体化选择。

局限性

  • 回顾性研究设计可能存在选择偏倚。
  • 未来需考虑生物学年龄和共病损害以评估个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Data on treatment approaches in geriatric melanoma patients are scant. Efficacy of oncologic treatments across age groups, with special focus on immunotherapy, and the impact of comorbidities were analyzed. METHODS: A retrospective multicenter cohort study of the ADOREG registry included patients with cutaneous melanoma, who received oncological drugs at German skin cancer centers between 2013 and 2023. Outcomes were objective response rate (ORR), progression-free survival (PFS), melanoma-specific survival (MSS), toxicities and reasons for treatment discontinuation. Age groups were prespecified as < 75 vs ≥ 75 years (geriatric), comorbidities were summarized by Charlson-Comorbidity-Index (CCI). Comparisons across groups were conducted with X2-test, survival outcomes were compared via log-rank tests. RESULTS: Of 14,356 melanoma patients, 8213 met the inclusion criteria, 6063 and 2150 were < 75 and ≥ 75 years old, respectively. Among the 3646 patients with metastatic disease, older patients received fewer treatment lines and were less likely to undergo surgery, radiotherapy and systemic therapy. However, efficacy of any first-line treatment did not differ between both age groups (p = 0.306). Immunotherapy selection at any line was similar in both groups (p = 0.109), but geriatrics were treated mainly with first-line anti-PD1 monotherapy, whereas combination ICIs was preferred in younger patients. Efficacy was not impaired (PFS and MSS: p > 0.05), while toxicity rates were lower. This pattern persisted across CCI categories. CONCLUSION: Age influenced treatment selection in melanoma patients. However, in geriatric patients, efficacy was not impaired, and a balanced toxicity profile was noticed, particularly for immunotherapy. Future studies considering biological age and impairment by comorbidities seems important to assess individualized treatment approaches.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lallas K, Nanz L, Ugurel S, et al. Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG. Eur J Cancer. 2026. PMID: 41747313. doi:10.1016/j.ejca.2026.116582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。